About ACT Biotech
ACT Biotech is a company based in San Francisco (United States) founded in 2008 was acquired by Eddingpharm in January 2014. ACT Biotech has raised $9.07 million across 4 funding rounds from investors including Eddingpharm and NGN Capital. ACT Biotech operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.07 M (USD)
in 4 rounds
-
Latest Funding Round
$1 M (USD), Series A
Jun 09, 2010
-
Investors
Eddingpharm
& 1 more
-
Employee Count
Not available
-
Acquired by
Eddingpharm
(Jan 08, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ACT Biotech
ACT Biotech has successfully raised a total of $9.07M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ACT Biotech
ACT Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eddingpharm and NGN Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
NGN Capital is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
Provider of biopharmaceutical products for critical illnesses
|
Locked | Locked | Locked |
Investor details for ACT Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ACT Biotech
Investment portfolio details for ACT Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ACT Biotech
Detailed financials for ACT Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Act Biotech Comparisons
Peer comparison for ACT Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ACT Biotech
ACT Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of ACT Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Act Biotech
Complete news archive for ACT Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ACT Biotech
ACT Biotech was founded in 2008.
ACT Biotech is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ACT Biotech is a funded company, having raised a total of $9.07M across 4 funding rounds to date.
ACT Biotech, is a biopharmaceutical company that develops oral small molecule kinase inhibitors as anti-cancer drugs. Its products include drugs with mechanisms of action in areas, such as signal transduction and anti-angiogenesis. The lead asset, Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer. The other two programs ACTB1003 (FGFRVEGFR2 inhibitor) and ACTB1010 (aurora kinases inhibitor) are in Phase I-ready and preclinical stages, respectively. In 2014, Chinese firm Eddingpharm acquired the global rights to Telatinib, ACTB1003 and ACTB1010 from ACT Biotech.
ACT Biotech's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
ACT Biotech has 2 investors. Key investors include Eddingpharm, and NGN Capital.